Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 27/07/18 at 10:36am

With the UK in the grip of a record-breaking heatwave, it's hard to focus on much else over here, but it's been another packed week in the pharma industry.

The Brexit farce continues as the UK Government has admitted that the NHS will need to stockpile medicines in the event no deal can be reached with the EU on an exit deal, and Roche and AstraZeneca have followed in Pfizer's footsteps with pledges to pause price hikes until 2019, after the latter firm was chastised over social media by President Donald Trump.

But the most-read story this week is the heart-breaking news that eleven babies have died during a trial of the erectile dysfunction drug Viagra.

And be sure not to miss Dr Peter jackson's feature on the threat of antimicrobial resistance and what we need to do to avert a future catastrophe, which has proved wildly popular on our Twitter.

Check out the week's ten most popular articles on Pharmafile.com now!

10. AstraZeneca jettisons European heart drug rights for $210m

AstraZeneca has announced its intention to hand over the European commercial rights to its heart failure and blood pressure treatment Atacand (candesartan) to German pharmaceutical firm Cheplapharm Arzneimittel for $210 million.

9. AstraZeneca announces price freezes while earnings drop by 28%

The Anglo-Swedish drug maker AstraZeneca has joined Pfizer and others in halting price hikes until the end of 2018.

8. Chinese premier slams drug maker after vaccine scandal

Chinese Premier Li Keqiang has spoken out against drug maker Changsheng Biotechnology after the Chinese firm was found to have forged production documents for a rabies vaccine.

7. NHS to stockpile drugs in preparation for no-deal Brexit

Secretary of State for Health and Social Care, Matt Hancock, has said that the NHS is preparing to stockpile medicines to safeguard against a  no-deal Brexit.

6. Roche join Pfizer and others in price freeze while critics pose questions

Swiss multinational Roche has joined Pfizer and others in halting price hikes. However critics have condemned the move as observers pointed out that the roll backs may be less meaningful than first impressions might suggest.

5. Amgen biosimilar proves non-inferior to J&J's Remicade in rheumatoid arthritis

Amgen has unveiled new Phase 3 data for its biosimilar version of Johnson & Johnson’s Remicade, confirming that it demonstrated non-inferiority compared to its reference product in the treatment of moderate-to-severe rheumatoid arthritis.

4. Gilead's CEO and Chairman to both step down before year's end

Gilead has announced that its President and Chief Executive Officer Dr John Milligan will be stepping down by the end of the year, ending his run of 28 years at the company. He will remain in the role while the Board of Directors searches for a successor.

3. Employees protest against shutting down of GSK facility in Bangladesh

Employees of the British multinational GlaxoSmithKline (GSK) have led a protest against the shutting down of manufacturing facilities in Bangladesh.

2. The mission against antimicrobial resistance

Two headlines have highlighted the ‘here and now’ of the threat of rising antimicrobial resistance (AMR), writes Dr Peter Jackson.

1. Eleven babies dead after Dutch viagra trial

A trial of the drug sildenafil, commonly sold under the brand name Viagra, has been halted immediately after the death of 11 babies.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches